{
    "nctId": "NCT01805089",
    "briefTitle": "Melatonin Versus Placebo in Breast Cancer",
    "officialTitle": "A Randomized Trial of Oral Melatonin Supplementation in Breast Cancer Survivors",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "EARLY_PHASE1",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 95,
    "primaryOutcomeMeasure": "Absolute Plasma Estradiol Levels After 4 Month Course of Melatonin or Placebo",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* History of ductal carcinoma in situ, lobular carcinoma in situ or stages 1-3 breast cancer\n* Not currently receiving chemotherapy or hormonal therapy\n* Postmenopausal\n\nExclusion Criteria:\n\n* Stage IV breast cancer or systemic recurrences\n* Prior malignancies of any type other than breast cancer, basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix\n* Use of adjuvant hormonal therapy, oral estrogen or progesterone replacement therapy, lutenizing hormone releasing hormone agonists currently or within the past 60 days\n* Concomitant use of beta-blockers\n* Concomitant nightly use of sleep aids at bedtime\n* Working more than one overnight shift per month on a regular basis\n* Concomitant use of postmenopausal hormone replacement therapy\n* Concomitant use of black cohosh, flaxseed or soy in pill or supplement form\n* Use of any type of oral melatonin supplementation within the past 30 days\n* Use of warfarin (coumadin) within the past 30 days\n* Active seizure disorder requiring the use of daily anti-epileptic medication",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}